Consumo de drogas médicas, medicamentos de venta libre y alcohol en adultos mayores / Consumption of medical drugs, over-the-counter medications and alcohol in elderlys / Consumo de drogas médicas, medicamentos de venda livre e álcool em idosos

Objetivo: realizar una revisión sistemática de la literatura para identificar los estudios que reportan la frecuencia del consumo drogas médicas, medicamentos de venta libre y alcohol, así como el consumo combinado de estas sustancias en los adultos mayores. Método: se utilizó como guía la Preferred Reporting Items for Systematic Reviews and Meta-Analyses, se identificaron 4,881 artículos a través de las bases de datos y tres artículos en el buscador google scholar, se eligieron doce estudios ya que cumplieron con los criterios de elegibilidad y por su calidad metodológica. Resultados: la revisión de la literatura permitió identificar que las drogas médicas más utilizadas fueron los benzodiacepinas, los sedantes, los antidepresivos y los psicotrópicos, los medicamentos de venta libre más usados fueron los analgésicos, laxantes, antiácidos y antihistamínicos; la combinación con el alcohol son prácticas observadas entre los adultos mayores. Conclusión: las drogas médicas y medicamentos de venta libre son consumidas para tratar los trastornos del sueño, depresión, ansiedad y estrés; con relación al alcohol entre el 20.3% y el 57.1% de los adultos mayores lo consumen; la combinación de alcohol y drogas médicas se observó entre el 9.3% y el 18.1%.(AU)

Objective: to perform a systematic review of the literature to identify the studies that report the frequency of consumption of medical drugs, over-the-counter medications and alcohol, as well as the combined use of these substances in the elderly. Method: the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes were used as a guide, 4,881 items through the databases and three items in the search google scholar were identified, twelve studies were chosen as they met the eligibility criteria and their methodological quality. Results: the literature review allowed us to identify that the most used medical drugs were benzodiazepines, sedatives, antidepressants and psychotropic drugs, the most used over-the-counter medications were analgesics, laxatives, antacids and antihistamines; the combination with alcohol are practices observed among the elderly. Conclusion: medical drugs and over-the-counter medications are consumed to treat sleep disorders, depression, anxiety and stress; in relation to alcohol between 20.3% and 57.1% of the elderly consume it; the combination of alcohol and medical drugs was observed between 9.3% and 18.1%.(AU)

Objetivo: realizar uma revisão sistemática da literatura para identificar os estudos que revelam a frequência do consumo de drogas médicas, medicamentos de venda livre e álcool, assim como o consumo combinado dessas substâncias em idosos. Método: foi utilizada como guia a Preferred Reporting Items for Systematic Reviews and MetaAnalyses, foram identificados 4,881 artigos através das bases de dados e três artigos no Navegador Google Scholar, foram selecionados doze exames já que cumpriram com os critérios de elegibilidade e pela sua qualidade metodológica. Resultados: a revisão da literatura permitiu identificar que as drogas médicas mais utilizadas foram as benzodiazepínicas, sedativos, antidepressivos e os psicotrópicos. Os medicamentos de venda livre mais usados foram os analgésicos, laxantes, antiácidos e anti-histamínicos. A combinação com o álcool é um comportamento observado nos idosos. Conclusão: as drogas médicas e medicamentos de venda livre são consumidos para o tratamento dos distúrbios do sono, depressão, ansiedade e estresse. Com relação ao álcool, entre 20.3% e 57.1% das pessoas idosas o consomem. A combinação de álcool e drogas médicas foi observada entre 9.3% e 18.1%.(AU)

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

BACKGROUND/AIMS: Bismuth-containing quadruple and moxifloxacin-based triple regimens are recommended as second-line therapy for Helicobacter pylori infection. The aim of this study was to compare the efficacy of each regimen. METHODS: From August 2004 to October 2012, a total of 949 patients (mean age, 54.32+/-12.08 years; male, 49.4%) who failed H. pylori eradication with a standard triple regimen were included. Patients treated with a bismuth-containing quadruple regimen for 7 and 14 days were designated as 7-BMT and 14-BMT, respectively, and those treated with a moxifloxacin-based triple regimen for 7 and 14 days were designated as 7-MA and 14-MA, respectively. H. pylori eradication was confirmed using the 13C-urea breath test, rapid urease test or histology. RESULTS: The eradication rates by 7-BMT, 14-BMT, 7-MA, and 14-MA were 66.4% (290/437), 71.1% (113/159), 53.1% (51/96), and 73.5% (189/257), respectively, by intention-to-treat analysis (ITT) and 76.5% (284/371), 83.8% (109/130), 55.6% (50/90), and 80.6% (187/232), respectively, by per-protocol analysis (PP). The eradication rates were higher in 14-BMT than 7-BMT by the ITT and PP analyses (p=0.277 and p=0.082, respectively). The 14-BMT and 14-MA treatments showed similar efficacies by ITT and PP (p=0.583 and p=0.443, respectively). CONCLUSIONS: The 7-BMT, 14-BMT, and 14-MA treatments showed similar and suboptimal efficacies. In both regimens, extending the duration of treatment may be reasonable considering the high level of antibiotic resistance in Korea.

Efficacy of Magnesium Trihydrate of Ursodeoxycholic Acid and Chenodeoxycholic Acid for Gallstone Dissolution: A Prospective Multicenter Trial

BACKGROUND/AIMS: Cholecystectomy is necessary for the treatment of symptomatic or complicated gallbladder (GB) stones, but oral litholysis with bile acids is an attractive alternative therapeutic option for asymptomatic or mildly symptomatic patients. This study was conducted to evaluate the efficacy of magnesium trihydrate of ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) on gallstone dissolution and to investigate improvements in gallstone-related symptoms. METHODS: A prospective, multicenter, phase 4 clinical study to determine the efficacy of orally administered magnesium trihydrate of UDCA and CDCA was performed from January 2011 to June 2013. The inclusion criteria were GB stone diameter or =50%, radiolucency on plain X-ray, and asymptomatic/mildly symptomatic patients. The patients were prescribed one capsule of magnesium trihydrate of UDCA and CDCA at breakfast and two capsules at bedtime for 6 months. The dissolution rate, response rate, and change in symptom score were evaluated. RESULTS: A total of 237 subjects were enrolled, and 195 subjects completed the treatment. The dissolution rate was 45.1% and the response rate was 47.2% (92/195) after 6 months of administration of magnesium trihydrate of UDCA and CDCA. Only the stone diameter was significantly associated with the response rate. Both the symptom score and the number of patients with symptoms significantly decreased regardless of stone dissolution. Adverse events necessitating discontinuation of the drug, surgery, or endoscopic management occurred in 2.5% (6/237) of patients. CONCLUSIONS: Magnesium trihydrate of UDCA and CDCA is a well-tolerated bile acid that showed similar efficacy for gallstone dissolution and improvement of gallstone-related symptoms as that shown in previous studies.

Bismuth subsalicylate as filler particle for an experimental epoxy-based root canal sealer

AIM: To evaluate the influence of bismuth subsalicylate addition in different concentrations on theproperties ofan experimental epoxy-based root canal sealer. METHODS: Bismuth subsalicylate in 20%, 40%, 60%, 80%, 100% and 120 wt% was added tothe sealer. Flow, film thickness, working time, setting time, dimensional change, sorption, solubility and cytotoxicity were evaluated according to ISO standard. Data were statistically analyzed by one-way ANOVA and Tukey'stest with a significance level of 5% for all tests. RESULTS:The flow, working and setting times significantly decreased withincreasing particle concentration. The film thickness, dimensional change, water sorption and solubility values significantly increased with higher particle amount. The results for cytotoxicity showed no statistically significant differences among the particle proportions. CONCLUSIONS: The results suggest that the addition up to 80% wt of bismuth subsalicylate appears to be a promising filler particle to root canal sealer development.

Pautas para reducir el número de prescripciones inadecuadas en pacientes con dispepsia / Guidelines to cut the number of inappropriate prescriptions in dyspepsia patients

Se considera demostrado que diferentes métodos de implementación dan como resultado un mayor o menor grado de aceptación de las pautas en atención primaria. Este estudio analiza el efecto sobre los gastos estimados en medicamentos a partir de tres métodos distintos de implementar las mismas pautas, utilizados en tres grupos diferentes de médicos generalistas. La investigación estuvo basada en: un método de implementación negociado, de nueve meses de duración (con incentivos económicos para completar el programa) (proyecto A); una sesión de un día de entrenamiento basado en la evidencia llevada adelante por colegas en pequeños grupos de trabajo (proyecto B); una reunión de aplicación conducida por un experto (proyecto C). Para cada proyecto comparamos los gastos estimados mensuales en inhibidores de la bomba de protones (IBP) y antagonistas de los receptores de histamina (ARH2) por cada mil pacientes registrados de los médicos generalistas (MG) que participaron con los de un grupo de MG de control, antes y después de implementar las pautas. Los 58 MG involucrados en el proyecto A redujeron las prescripciones en IBP alrededor del 26% (4 564 euros vs. 6 201 euros para 222 controles, p = 0.057) y de ARH2 alrededor de 30% (954 vs. 1 365 euros; p = 0.026). Los 101 MG que participaron del proyecto B prescribieron 5 535 euros en IBP y 556 euros en bloqueantes H2, mientras que los 61 MG controles hiceron prescripciones por 5 732 y 706 euros, respectivamente (lo que significó un ahorro del 3% en IBP y 21% en ARH2; p = ns). Los 15 MG que estuvieron en el proyecto C prescribieron 2 479 euros en IBP y 1 258 euros en ARH2, lo que implica un gasto 12% superior en IBP y una reducción del 17% en ARH2 cuando se los compara con los 2 215 euros empleados en IBP y 1 524 euros en bloqueantes H2 por los 270 MG del grupo control (p = ns)...

Efficacy of Levofloxacin-based Triple Therapy as Second-lineHelicobacter pylori Eradication / 대한소화기학회지

BACKROUND/AIMS: Bismuth-based quadruple therapy for second-line eradication treatment achieves the eradication rate ranging from 70% to 81% due to antimicrobial resistance and poor compliance. The aim of this study was to compare the eradication rate of levofloxacin-based triple therapy with that of bismuth-based quadruple therapy in second-line Helicobacter pylori (H. pylori) eradication therapy. METHODS: Seventy-six outpatients with persistent H. pylori infection after first-line triple therapy were enrolled in this prospective randomized trial. The subjects were randomized to receive levofloxacin 300 mg, amoxicillin 1 g, and pantoprazole 20 mg, given twice daily for 7 days (LAP group), or metronidazole 500 mg twice, tetracycline 500 mg four times, and pantoprazole 20 mg twice, bismuth subcitrate 600 mg twice daily for 7 days (MTPB group). Eradication was confirmed with 13C-urea breath test or rapid urease test 4 weeks after the cessation of therapy. RESULTS: Among Seventy-six patients initially included, eleven were lost during follow-up. The eradication rates, expressed as intention to treat (ITT) and per protocol (PP) analyses, were 51.6% and 53.3% in the LAP group, and 48.9% and 62.9% in the MTPB group, respectively. There was no significant difference in H. pylori eradication rates between the two groups (p=0.815 by ITT, p=0.437 by PP). LAP regimen was better tolerated than MTPB regimen with lower incidence of side effects (10.0% versus 31.4%, p=0.03). CONCLUSIONS: H. pylori eradication rates of levofloxacin-based triple therapy and bismuth-based quadruple therapy were not significantly different in second-line H. pylori eradication therapy, and low incidence of side effects was observed in levofloxacin-based triple therapy.

Effects of a single low dose of ranitidine and effervescent antacids on intragastric acidity in healthy volunteers / Efectos de bajas dosis de ranitidina y antiácidos efervescentes sobre la acidez intragástrica en voluntarios sanos

Introduction/aims: We hypothesized that a combination of an effervescent antacid and ranitidine could allow immediate and long-lasting increase intragastric acidity. Our aim was to determine the effect of the combined intake of both, of a low dose ranitidine (OTC) and 5g of antacid on gastric pH. Material and methods: Twenty healthy Helicobacter pylori negative volunteers were enrolled. The study consisted in a fasting 6-hour gastric ph-metric procedure performed in two different periods: baseline (1-hour before drug) and post-drug (5-hours) after oral administration of a single dose of ranitidine (75 mg) plus 5 g of a commercial composed alkaline (sodium bicarbonate, citric acid, sodium carbonate). Results: While two subjects did not complete the pH-metry analysis due to technical reasons, 18 volunteers were finally assessed. Baseline intragastric pH (1.3±0.1) (mean±SD) rose significantly after administration of the drug (mean pH value for the whole period: 5.1±0.3; p<0.00001). The pH increased after administration of the study combination and values higher than pH 3 and pH 4 were reached immediately (median time: 27 sec, range: 0- 189 and 54 sec, range 27-3,600 sec, respectively). Gastric pH was initially maintained above 4 for 23.0±5 minutes. The mean time lapsed with pH<4 during the post-drug period was 96±17 min (32% of the total time). Conclusion: Our study confirms the fast and persistent effect produced by the administration of a combination of antacid salts plus low dose of ranitidine. We suggest that the given combination could be effeceffective, fast and safe for sporadic pyrosis or mild grastroesophageal reflux symptoms.

Introducción/objetivos: la combinación de un antiácido efervescente y ranitidina podría brindar un descenso inmediato y prolongado de la acidez intragástrica. Nuestro objetivo fue determinar el efecto de la ingesta conjunta de ambos (75 mg de ranitidina y 5 g de antiácidos) sobre el pH gástrico. Material y métodos: se incluyeron 20 voluntarios sanos, con anticuerpos anti- Helicobacter pylori negativos. Se realizó, en condiciones de ayuno, una pH-metría gástrica de 6 horas en dos períodos: basal (1 hora antes del medicamento) y post-droga (5 horas) luego de la administración oral de una dosis única de ranitidina (75 mg) + 5 g de antiácidos efervescentes (bicarbonato sódico, ácido cítrico, carbonato sódico). Resultados: dado que dos pacientes no completaron el estudio de pH por razones técnicas, se analizaron los resultados de 18 voluntarios. El pH intragástrico basal fue de 1.33±0.12 (promedio ± DS) y se elevó a 5.1±0.3 como promedio de todo el período post-droga (p<0.00001). El incremento de pH fue inmediato; así los valores de pH=3 y pH=4 fueron alcanzados en 27 seg, rango: 0-189 y 54 seg, rango 27- 3.600, respectivamente (mediana, rango). El pH se mantuvo inicialmente por encima de 4 durante 23.0±5 minutos. El tiempo con pH < 4 durante las 5 horas post-droga fue de 96± 17 minutos (32% del tiempo total). Conclusión: nuestro estudio confirma el efecto rápido y persistente determinado por la combinación de sales antiácidas y bajas dosis de ranitidina. De este modo esta asociación podría ser efectiva, rápida y segura frente a pirosis esporádica o síntomas de reflujo gastro-esofágico leve.

Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole.

BACKGROUND & OBJECTIVE: Omeprazole treats gastro-oesophageal reflux disease (GORD) by inhibition of acid secretion whereas alginate based reflux suppressants work by forming a low density raft of near neutral pH which floats on the stomach contents and physically impedes gastro-oesophageal reflux. There is limited pharmacokinetic information regarding possible drug interaction between these two types of products, although these may be frequently co-prescribed to improve symptom control in GORD patients. This study was designed to determine whether the administration of a 10 per cent w/v liquid alginate suspension affected the pharmacokinetic profile of omeprazole. METHODS: This was a randomized, two-treatment, two-sequence, two-period crossover study in 26 volunteers. Each treatment was dosed for 3 consecutive days with a washout period of 7 days between dosing periods. Blood samples for pharmacokinetic analysis were taken over the 24 h period following the final dose of omeprazole. RESULTS: Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%). Mean values for T(max), K(el) and T(1/2) were also similar for the two treatment regimens. INTERPRETATION & CONCLUSION: As the 90 per cent confidence intervals for the geometric mean ratios for C(max), AUC(0-t), and AUC(0-alpha) are all contained within the bioequivalence interval of 80-125 per cent, it can be concluded that the administration of this liquid alginate suspension does not affect the pharmacokinetic profile of omeprazole.

Trial of Moxifloxacin-containing Triple Therapy after Initial and Second-line Treatment Failures for Helicobacter pylori Infection / 대한소화기학회지

BACKGROUND/AIMS: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. METHODS: The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. RESULTS: The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). CONCLUSIONS: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.

The Trend of Eradication Rates of Second-Line Quadruple Therapy Containing Metronidazole for Helicobacter pylori Infection: An Analysis of Recent Eight Years / 대한소화기학회지

BACKGROUND/AIMS: Failure rates of Helicobacter pylori eradication treatment turned out to be exceeding 10%, causing recurrence of peptic ulcers. In the case of eradication failure, the Korean College of Helicobacter Research and Practice recommends quadruple therapy consisting of proton pump inhibitor, bismuth, tetracycline and metronidazole. Many reports regarding the eradication rates of quadruple therapy have been reported. However, most were limited by short follow-up periods. Hence, we evaluated the efficacy of the metronidazole containing quadruple therapy as a second line treatment from April, 1996 through July, 2004. METHODS: Sixty-three patients were enrolled. Treatment consisted of aforementioned quadruple therapy for 1 week. Four to six weeks after completion of treatment, biopsies and CLO tests were performed to detect the presence of H. pylori. The patients were then followed-up with upper endoscopy once every year. RESULTS: The efficacy of the quadruple therapy was 74.6% in intention-to-treat analysis and 83.9% in per protocol analysis. Eradication rates of the years 1996, 1999-2000, 2001, and 2002-2004 were 75.0%, 93.8%, 100%, and 72.7%, respectively. CONCLUSIONS: Our data can not reveal the evidence of decreasing trend for eradication rate quadruple therapy of H. pylori in 8 years. However, eradication rate of 72.7% in recent 2 years necessitates the development of more efficient eradication regimen.

Effectiveness of Triple Therapy and Quadruple Therapy for Helicobacter pylori Eradication / 대한소화기학회지

BACKGROUND/AIMS: Quadruple therapy can be considered as a first-line therapy in areas where the resistance rate to clarithromycin is high. Comparison study of triple therapy and quadruple therapy for Helicobacter pylori (H. pylori) eradication is still lacking in Korea despite the increasing prevalence of antibiotic resistance. This study was conducted to compare the efficacy of triple and quadruple therapy as a first-line treatment in H. pylori infected patients with peptic ulcer. METHODS: Consecutive 149 cases of peptic ulcer disease associated with H. pylori infection were randomized either to proton pump inhibitor (PPI, bid), amoxicillin (1,000 mg, bid), and clarithromycin (500 mg, bid) (PAC group) or to PPI (bid), bismuth subcitrate (300 mg, qid), metronidazole (500 mg, tid), and tetracycline (500 mg, qid) (PBMT group) eradication treatments for 7 days. Outcome of eradication therapy was assessed by 13C-urea breath test performed 4-6 weeks after eradication. RESULTS: Eradication rates in PAC and PBMT group were 78.7% (59/75) and 71.6% (53/74) by intention to treat analysis, respectively (p=0.424). By per protocol analysis, eradication rates of PAC and PBMT group were 85.5% (59/69) and 85.5% (53/62), respectively (p=1.012). Adverse reactions occurred in 5 (6.6%) and 7 (9.5%) patients in PAC and PBMT group, respectively (p=0.346). CONCLUSIONS: One week-quadruple therapy as a first-line treatment for H. pylori infection does not offer any advantage over PPI-based triple therapy in Korean patients.

Efficacy of 14 Day OBMT Therapy as a Second-line Treatment for Helicobacter pylori Infection / 대한소화기학회지

BACKGROUND/AIMS: As a second-line treatment for H. pylori eradication in the case of first-line OAC (omeprazole, amoxicillin, clarithromycin) treatment failure, a minimum of one-week OBMT quadruple therapy composed of omeprazole, bismuth, metronidazole, tetracycline has been recommended in European countries and one or two weeks in USA. In Korea, one-week OBMT quadruple therapy is recommended for the case of first-line OAC treatment failure. Because H. pylori eradication rate of one-week OBMT therapy in Korea is about 80%, the eradication rate of one week therapy is not satisfactory. We analyzed the effect of two-week second-line OBMT therapy. METHODS: Between June 2002 and June 2003, 107 patients who were H. pylori positive (44 males and 63 females: mean age 51.8 years) after primary eradication therapy received two-week OBMT therapy. Four weeks after completion of therapy, 13C-urea breath test was performed to detect H. pylori. RESULTS: After two weeks of OBMT therapy, eradication was achieved in 103 of 107 patients (96.3%) and in 68 of 71 peptic ulcer patients (95.8%). CONCLUSIONS: Two-week OBMT therapy should be considered as a retreatment regimen with the eradication rate more than 90%.

Papel do pantoprazol em baixa dose no tratamento ambulatorial da dispepsia funcional, das gastrites e da esofagite de refluxo leve / Role of low-dose pantoprazole in outpatient treatment of functional dyspepsia, gastritis, and mild gastroesophageal reflux disease

Sintomas dispépticos säo queixas comuns na prática clínica diária. Apenas uma minoria destes pacientes tem alguma alteraçäo estrutural que explique os sintomas. A maioria nlo apresenta lesöes estruturais, sendo, portanto, rotulada como portadora de dispepsia funcional ou DRGE sem esofagite. Muitos säo inadequadamente rotulados como portadores de gastrite A inibiçäo da secreçäo ácida é um elo comum na abordagem terapêutica destas afecçöes. O objetivo do presente estudo foi a avaliaçäo do papel do pantoprazol 20 mg no alívio sintomático da dispepsia funcional, das gastrites e no tratamento da doença do refluxo gastroesofágico sem esofagite ou da esofagite de refluxo leve. Num estudo aberto e multicêntrico foram incluídos 5.105 pacientes ambulatoriais, divididos em quatro grupos: Grupo 1:DRGE com 641 pacientes (12,6 porcento), Grupo 2:DF com 1709 pacientes(33,5 porcento), Grupo 3:gastrites com 2.105 pacientes(41,2 porcento), Grupo 4: outros(diagnósticos mistos: DRGE e DF, DRGE e gastrites, DF e gastrites) com 650 pacientes (12,7 porcento). Todos os sintomas gastrointestinais avaliados apresentaram melhora estatísticamente significante no pós-tratamento quanto comparados ao quadro inicial. Com o término do tratamento, a ausencia dos sintomas foi observada em cerca de 80 porcento a 95 porcento dos pacientes. Reaçöes adversas foram descritas em 1 porcento dos pacientes durante o tratamento com pantoprazol, sendo as mais observadas cefaléias, constipaçlo intestinal e diarréia. O presente estudo demonstrou uma eficácia significativa näo apenas em relaçäo a remissäo dos sintomas da dispepsia do tipo úlcera, mas também de sintomas característicamente descritos como motores, como a sensaçäo de plenitude gástrica ou empachamento, saciedade precoce, retardo do esvaziamento gástrico, náuseas e vômitos com o uso diário de 20 mg de pantoprazol durante uma média de três semanas. O alívio sintomático da dispepsia funcional, das gastrites e no tratamento da doença de refluxo gastroesofágico sem esofagite ou da esofagite de refluxo leve foi significativo com excelente tolerabilidade e segurança.

Dispepsia funcional / Functional dyspepsia

As micoses superficisis säo as infecçöes mais comuns do tegumento cutâneo, envolvendo as partes queratinizadas, semiqueratinizadas, mucosas e os anexos pêlos e unhas.(au)

Effect of intraesophageal acid instillation on airway reactivity in patients with asthma.

OBJECTIVE: To study the change in airway reactivity due to presence of acid in lower esophagus and its reversibility by antacid. METHOD: In this double blind study 12 subjects with asthma and gastroesophageal reflux received acid (N/10 hydrochloric acid) and antacid (mixture of magnesium trisilicate and aluminum hydroxide) perfusion in lower esophagus via a nasogastric tube. The four combinations were antacid-antacid (control), antacid-acid, acid-antacid and acid-acid. Airway reactivity (Histamine PD20) was recorded after each perfusion. RESULTS: Histamine PD20 significantly decreased (airway reactivity increased) (p < 0.05) with all three combinations containing acid as compared to control. No significant difference in airway reactivity was observed if the antacid was given before or after the acid. CONCLUSION: Presence of acid in lower esophagus can increase airway reactivity. This effect lasts longer than the presence of acid in esophagus itself.

Estudio multicéntrico con pantoprazol en el tratamiento de la enfermedad ácido péptica e México / Multicentric study using pantoprazole in the treatment of peptic acid disease in Mexico

Se realizó un estudio prospectivo multicéntrico en diversas ciudades de la República Mexicana utilizando pantoprazol para el tratamiento de la enfermedad ácido-péptica. Se incluyeron 1,696 pacientes con diagnóstico de enfermedad ácido-péptica. Se recabaron datos personales y relacionados con la enfermedad, método de diagnóstico, tratamiento y resultado al final del mismo. Se encontró que la media de edad en los pacientes del sexo masculino fue 43.9 años y en las mujeres 42.4 años (p = 0.041). El porcentaje de hombres y mujeres fue de 49.6 respectivamente. Existe correlación entre el consumo de alcohol, el diagnóstico de úlcera péptica (p = 0.032) y el dolor epigástrico en ayunas (p = 0.004). De los diagnósticos establecidos, la gastritis tuvo la mayor proporción (21.19 por ciento). Al final del tratamiento, 68 por ciento (1.157 casos) reportaron ausencia total de los síntomas que los motivaron a buscar atención médica. El 96.26 por ciento de los tratamientos se ajustaron a la dosis diaria recomendada de 40 mg. La evaluación global sobre el tratamiento con pantoprazol en relación con los casos tratados fue que 96 por ciento de los investigadores lo consideraron excelente o bueno. Los resultados obtenidos demuestran la efectividad del pantoprazol en el tratamiento de la enfermedad ácido-péptica, con la dosis recomedada de 40 mg al día. En sólo dos casos se suspendió el tratamiento por probables reacciones adversas al medicamento

Evaluation of antacid gel preparations available commercially in the Indian market.

A scoring system based on the neutralising capacity, cost efficiency and time of buffering of twenty four commercially available antacid gels was analysed. A gel scoring eight out of the ten points was considered as the best antacid. The study provides a practical guide in choosing a quick neutralizing and low cost antacid gel.